The Axcellant team recently attended the International Conference on Nuclear Cardiology (ICNC) in Berlin – one of the most important global scientific meetings dedicated to cardiovascular imaging, nuclear medicine, and emerging diagnostic technologies.
For companies operating at the intersection of imaging, radiopharmaceuticals, and precision medicine, conferences such as ICNC are more than scientific events. They are where the future direction of clinical development becomes visible – from new imaging biomarkers and AI-supported diagnostics to the operational realities of translating innovative tracers into multicentre clinical studies.
This year’s program made one thing particularly clear: nuclear cardiology is entering a new phase of maturity and clinical relevance.
Artificial intelligence was one of the conference’s dominant themes. Scientific sessions focused heavily on how machine learning is now moving beyond experimental use cases and becoming integrated into real-world nuclear imaging workflows.
Experts discussed the growing role of AI in myocardial perfusion quantification, automated image interpretation, and reduction of inter-observer variability – all critical areas for improving diagnostic confidence and standardizing imaging-based decision-making.
For organizations involved in imaging-intensive clinical development, this shift has significant implications. As nuclear medicine studies become increasingly data-driven, sponsors require not only scientific expertise but also operational partners capable of managing complex imaging endpoints, harmonized acquisition protocols, and high-quality data interpretation across multiple sites.
These are precisely the kinds of challenges Axcellant was built to support. The company’s focus on nuclear medicine and advanced imaging allows it to combine clinical operations with a deep understanding of imaging physics, radiopharmaceutical logistics, and quantitative imaging methodologies – capabilities that are becoming increasingly important as AI-supported imaging enters mainstream clinical practice.
Another major topic at ICNC was the rapid evolution of next-generation radiopharmaceuticals and molecular imaging agents.
Among the most discussed innovations were FAPI-based tracers, which are opening new possibilities for assessing myocardial fibrosis and inflammation – clinical areas where traditional imaging methods have historically faced significant limitations.
Researchers also highlighted the growing role of amyloid imaging tracers in cardiology. Originally associated primarily with neurology applications, these tracers are now proving increasingly valuable for detecting cardiac amyloidosis, helping improve the diagnosis of a condition that has long remained underrecognized in routine clinical practice.
For Axcellant, these developments closely reflect the broader transformation underway across nuclear medicine. The industry is rapidly moving toward more targeted, biologically driven diagnostics and theranostic approaches – an evolution that requires highly specialized expertise in radiopharmaceutical development, imaging strategy, dosimetry, and regulatory planning.
As a CRO focused specifically on nuclear medicine and molecular imaging, Axcellant supports sponsors across the full development pathway – from early clinical strategy and feasibility through complex multicentre studies involving PET, SPECT, and advanced imaging endpoints.
Beyond the scientific sessions, ICNC also created an important environment for strategic collaboration and exchange among clinical researchers, imaging specialists, and industry partners.
During the conference, the Axcellant team had the opportunity to meet with internationally recognized experts, including Professor Piotr Słomka and Professor Juhani Knuuti – two influential voices helping shape the future of quantitative imaging and AI-supported nuclear cardiology.
Conversations focused not only on scientific innovation but also on the practical challenges of translating advanced imaging technologies into robust clinical development programs. Topics such as imaging standardization, reproducibility of quantitative endpoints, and the integration of novel tracers into clinical trials remain central to advancing nuclear medicine.
For a specialized CRO operating in this field, these discussions are invaluable. Effective radiopharmaceutical development depends not only on operational execution but also on close collaboration with investigators, imaging experts, and academic centers that can advance the science itself.
The pace of innovation presented at ICNC reinforced how rapidly the nuclear medicine landscape is evolving – particularly in cardiology, oncology, and theranostics.
As imaging technologies become more sophisticated and radiopharmaceutical pipelines continue to grow, sponsors increasingly need development partners who understand both the scientific complexity and the operational realities unique to this field. Managing radioactive tracers, coordinating imaging-heavy study designs, ensuring site readiness, and navigating regulatory expectations all require specialized expertise that goes far beyond standard clinical trial management.
Axcellant continues to strengthen its position in this space by combining scientific understanding with hands-on experience in imaging-focused clinical development. Through collaboration with global experts, academic institutions, and innovative sponsors, the company remains closely connected to the advances shaping the future of nuclear medicine and molecular imaging.
📩 Reach out to learn how Axcellant can support your program
Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…
The FDA and the European Commission are changing the rules of the game simultaneously. The shift is from a single…
Modern nuclear medicine is a high-tech discipline that requires advanced facilities, infrastructure, qualified staff, and know-how. The reliable supply of radionuclides,…
Copyright @ 2026 Axcellant